{"issuance_frequency":"","notes_translated":{"fr":"Par suite de l’examen, de l’autorisation et de la surveillance des drogues contre la COVID-19 en vertu du Règlement, les fabricants peuvent bénéficier des protections en matière de propriété intellectuelle qui sont disponibles à l’égard d’une présentation qui donne lieu à un AC. ","en":"As a consequence of the review, authorization and oversight of COVID-19 drugs under the Regulations, manufacturers may benefit from intellectual property protections that are available in respect of a submission that results in an NOC."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"153eae83-abe0-4fab-b287-f71cff619e30","metadata_created":"2021-07-29T12:12:06.118611","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-29T12:12:06.118617","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-29","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["COVID-19","pandémie","médicament COVID-19","modification","Règlement sur les aliments et drogues","médicaments","fabricants","présentation","avis de conformité","protections de la propriété intellectuelle"],"en":["COVID-19","pandemic","COVID-19 drug","amendement","Food and Drug Regulations","drugs","manufacturers","submission","notice of compliance","intellectual property protections"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Lignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19 : Propriété intellectuelle","en":"Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"153eae83-abe0-4fab-b287-f71cff619e30","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"e578f094-9cc4-4086-9c10-0c6985ea03cf","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19 : Propriété intellectuelle","en":"Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property","language":["en"],"created":"2021-07-29T12:12:06.176414","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/food-drug-regulations-amendments-covid-19/intellectual-property.html","last_modified":null,"position":0,"revision_id":"e326b9b9-88b0-4cbe-9749-fcb72d15c304","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"153eae83-abe0-4fab-b287-f71cff619e30","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4be89fe9-1852-4fed-9185-8abcdb1081ee","related_relationship":"","name_translated":{"fr":"Lignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19 : Propriété intellectuelle","en":"Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property","language":["fr"],"created":"2021-07-29T12:12:06.176420","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/reglement-aliments-drogues-modifications-covid-19/propriete-intellectuelle.html","last_modified":null,"position":1,"revision_id":"e326b9b9-88b0-4cbe-9749-fcb72d15c304","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-06-24 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"153eae83-abe0-4fab-b287-f71cff619e30","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"As a consequence of the review, authorization and oversight of COVID-19 drugs under the Regulations, manufacturers may benefit from intellectual property protections that are available in respect of a submission that results in an NOC.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19: Intellectual property","revision_id":"e326b9b9-88b0-4cbe-9749-fcb72d15c304"}